Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials

Université Pierre et Marie Curie. Paris, France./ Hôspital Pitié-Salpêtrière. Service de las Maladies Infectieuses et Tropicales. Paris, France.
Hospital Universitari Germans Trias i Pujol. Barcelona, España./ IrsiCaixa Fundación. Barcelona, España.
Private Practice. Los Angeles, CA, USA.
Clinique Médicale I'Actuel. Montreal, QC, Canada.
Hôspital Saint-Louis. Service de las Maladies Infectieuses et Tropicales. Paris, France./ University of Paris Diderot. Paris, France.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Kaiser Permanente. Los Angeles, California, USA.
University of California San Diego. Division of Infectious Diseases. San Diego, CA, USA.
Tibotec BVBA. Beerse, Belgium.
Tibotec BVBA. Beerse, Belgium.
Tibotec BVBA. Beerse, Belgium.
Tibotec Inc. Titusville, NJ, USA.

Abstract

Durable efficacy and long-term safety of antiretroviral therapy are important goals in the management of treatment-experienced patients. The 96-week efficacy and safety of the non-nucleoside reverse transcriptase inhibitor (NNRTI) etravirine were evaluated in the Phase III DUET trials.

Keywords

HIV-1
Double-Blind Method
Darunavir
Reverse Transcriptase Inhibitors
Ritonavir
Treatment Outcome
Etravirine

Citation

KATLAMA, Christine. et al. Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials. Antiviral Therapy, v. 15, n. 7, p. 1045-1052, 2010.

DOI

10.3851/IMP1662

ISSN

1359-6535

Please use this identifier to cite or link to this item: https://www.arca.fiocruz.br/handle/icict/30173

Type

Copyright

Restricted access

Embargo date

2025-08-30

Collections

Share

Statistics

Metadata

Author

Affilliation

Abstract

Keywords

Citation

DOI

ISSN